This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous chemotherapy treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,692
The primary objective of this study is to compare overall survival for ZD1839 plus best supportive care versus placebo plus best supportive care
· ZD1839 + BSC versus Placebo + BSC in terms of time to treatment failure
· ZD1839 + BSC versus Placebo + BSC in terms of investigator assessed overall
· objective tumour response (CR + PR)
· ZD1839 + BSC versus Placebo + BSC in terms of tolerability
· ZD1839 + BSC versus Placebo + BSC in terms of quality of life changes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Capital Federal, Buenos Aires, Argentina
Research Site
Bahía Blanca, Argentina
Research Site
Buenos Aires, Argentina
Research Site
La Plata, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Santa Fe, Argentina
Research Site
Concord, New South Wales, Australia
Research Site
Potts Point, New South Wales, Australia
Research Site
St Leonards, New South Wales, Australia
...and 201 more locations